Ampio Pharma rises on positive data from joint disease study

Ampio Pharmaceuticals

15/09/2021 15:04

** Drug developer's shares  AMPE.A  rise ~12% to $1.61
    ** Co reports positive results from late-stage study testing
intra-articular injection of Ampion in adults with pain due to
severe osteoarthritis of the knee (OAK)  urn:newsml:reuters.com:*:nPn3pl8Bpa
    ** Ampion demonstrated statistically significant reduction
in pain and improvement in function at 12 weeks in patients
    ** OAK is a degenerative joint disease of the knee. It is
typically the result of wear and tear and progressive loss of
articular cartilage
    ** AMPE plans to meet with U.S. FDA to discuss the results
and its drug approval application

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))